灯盏细辛口服液对急性冠状动脉综合征患者外周血C-反应蛋白、MCP-1 和MMP-9 水平的影响

目的:探讨灯盏细辛口服液对急性冠状动脉综合征患者外周血C-反应蛋白、1-甲基环丙烯和9-基质金属蛋白酶水平的影响。方法:选取我院心内科已确诊为急性冠状动脉综合征的患者110例,随机分为实验组和对照组,对照组行常规药物治疗,实验组在对照组的基础上口服灯盏细辛口服液。比较两组患者治疗前后外周血C-反应蛋白变化情况及MCP-1及MMP-9水平及临床疗效。结果:与治疗前相比,两组患者治疗后MCP-1、MMP-9及C-反应蛋白水平降低(P0.05),与对照组相比,实验组患者MCP-1、MMP-9及C-反应蛋白较低(P0.05);与对照组相比,实验组总有效率较高(P0.05)。结论:灯盏细辛口服液对急性冠状动脉综合征患者具有较好的疗效,这可能与其降低外周血中C-反应蛋白、MMP-9和MCP-1水平具有一定的关系。

Effect of Erigeron Breviscapus Oral Liquid on the C- reactive Protein, MCP-1 and MMP-9 Levels in Peripheral Blood by in Patients with Acute Coronary Syndrome

Objective:To investigate the effect of the C- reactive protein, MCP-1 and MMP-9 levels in peripheral blood by erigeron breviscapus oral liquid in patients with acute coronary syndrome.Methods:110 patients with acute coronary syndrome from department of Cardiology in our hospital were selected and randomly divided into the control group and the experiment group. The C- reactive protein, MCP-1 and MMP-9 levels in peripheral blood were tested and compared before and after treatment.Results:Compared with before treatment, the levels of MCP-1, MMP-9 and C- reactive protein were lower (P<0.05). Compared with the control group after treatment, the levels of MCP-1, MMP-9 and C- reactive protein were lower(P<0.05), the total effective rate were higher(P<0.05).Conclusion:Erigeron breviscapus oral liquid can reduce the acute coronary artery syndrome in patients with peripheral blood C reactive protein, MCP-1 and MMP-9 levels, of acute coronary artery comprehensive syndrome clinical treatment has important clinical significance.